Brought to you by 
Bionomics partners anxiety candidate BNC210 with Ironwood; terminated
12 Nov 2014
Executive Summary
Australian drug discovery company Bionomics Ltd. has licensed Ironwood Pharmaceuticals Inc. (focused on the GI medicine linaclotide) global rights to develop and market its Phase Ib anxiety treatment BNC210 as well as follow-on candidates.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bionomics partners anxiety candidate BNC210 with Ironwood; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice